

# Antidepressant Use in Cancer Patients

## Appendix

**Supplemental Table A1. Multivariable Logistic Regression for Exposure to SSRI/SNRIs**

Covariate	Case-finding method*	(1)		(2)		(3)		(4)		(5)	
		OR	<i>P</i> value	OR	<i>P</i> value	OR	<i>P</i> value	OR	<i>P</i> value	OR	<i>P</i> value
<b>Depression diathesis</b>											
Depressive symptoms*	Yes vs. no	1.71	<0.001	1.39	0.017	1.04	0.743	1.74	<0.001	2.20	<0.001
Family history of depression	Yes vs. no	2.16	<0.001	2.19	<0.001	2.28	<0.001	2.22	<0.001	2.23	<0.001
<b>Comorbidity indicators</b>											
Number of medicines	5-9 vs. 0-4	2.10	<0.001	2.16	<0.001	2.14	<0.001	2.15	<0.001	2.23	<0.001
	≥10 vs. 0-4	3.27	<0.001	3.39	<0.001	3.45	<0.001	3.37	<0.001	3.49	<0.001
	Missing vs. 0-4	1.52	0.039	1.55	0.034	1.52	0.048	1.43	0.083	1.50	0.061
Pain management index	Adequately treated vs. under-treated	1.10	0.502	1.06	0.655	1.00	0.991	1.01	0.925	1.00	0.971
	Missing vs. under-treated	1.74	0.065	1.79	0.059	1.31	0.351	1.86	0.018	1.72	0.050
Exposure to steroids	Yes vs. no	0.79	0.125	0.77	0.100	0.76	0.109	0.74	0.063	0.77	0.111
Exposure to anxiolytics	Yes vs. no	2.04	<0.001	2.07	<0.001	2.17	<0.001	2.03	<0.001	2.15	<0.001
Exposure to sedatives	Yes vs. no	2.13	<0.001	2.08	<0.001	2.16	<0.001	2.10	<0.001	2.11	<0.001
Exposure to beta-blockers	Yes vs. no	0.84	0.130	0.84	0.139	0.85	0.164	0.88	0.269	0.87	0.206
<b>Cancer treatment status</b>											
Current therapy	Within 1 month vs. no	0.82	0.220	0.82	0.249	0.80	0.175	0.81	0.203	0.83	0.274
	Within 1 year vs. no	0.88	0.361	0.88	0.397	0.88	0.358	0.89	0.447	0.93	0.605
	>1 year vs. no	1.54	0.003	1.53	0.004	1.51	0.007	1.57	0.002	1.57	0.004
Prior systemic therapy	Yes vs. no	1.46	0.002	1.49	0.001	1.45	0.002	1.48	0.002	1.50	0.001
Prior radiotherapy	Yes vs. no	1.13	0.290	1.12	0.327	1.14	0.234	1.09	0.434	1.11	0.382
<b>Clinical/Demographic</b>											
Type of institution	CCOP vs. academic	1.84	0.017	1.83	0.014	1.83	0.017	1.80	0.011	1.83	0.018
	MBCCOP vs. academic	1.47	0.238	1.51	0.212	1.55	0.186	1.49	0.215	1.52	0.232
Race/ethnicity	other vs. Non-Hispanic White	0.50	<0.001	0.49	<0.001	0.50	<0.001	0.51	<0.001	0.49	<0.001
Sex	Male vs. Female	0.54	<0.001	0.53	<0.001	0.53	<0.001	0.55	<0.001	0.54	<0.001
Age	<55 vs. ≥55	1.26	0.038	1.28	0.025	1.31	0.015	1.25	0.051	1.28	0.022
Duration of cancer	Continuous (years)	0.99	0.488	0.99	0.542	0.99	0.501	0.99	0.404	0.99	0.602
Disease status	advanced vs. Non-advanced	0.91	0.270	0.91	0.247	0.91	0.252	0.86	0.093	0.89	0.186
ECOG PS	1-4 vs. 0	0.93	0.541	0.94	0.598	0.99	0.905	0.95	0.649	0.96	0.759
Weight loss in past 6 months	>5% vs. ≤5%	0.82	0.328	0.82	0.316	0.83	0.337	0.81	0.259	0.86	0.453
Participating in counseling	Yes vs. no	1.63	0.037	1.69	0.023	1.76	0.015	1.58	0.050	1.59	0.050
Participating in support	Yes vs. no	1.08	0.685	1.08	0.668	1.09	0.624	1.17	0.389	1.11	0.569
Perceived QOL	Poor vs. good	1.33	0.012	1.39	0.004	1.49	0.001	1.38	0.008	1.42	0.003

Abbreviations: SSRI, serotonin-reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; ECOG PS, Eastern Cooperative Oncology

Group performance status; QOL, quality of life; CCOP, Community Clinical Oncology Program; MBCCOP, Minority-Based Community

Clinical Oncology Program

\*Depressive symptoms case-finding category: (1) sadness/ depression ≥ 4; (2) distress ≥ 4; (3) interference with mood ≥ 7 or enjoyment ≥ 7; (4)

presence of psychological distress (per clinician-report); (5) depression being listed as one of top three symptoms (per clinician-report)